Woven Planet Holdings, a Subsidiary of Toyota, to Acquire CARMERA
Woven Planet Holdings, Inc. (“Woven Planet”), a subsidiary of the Toyota Motor Corporation, announced the acquisition of CARMERA, Inc. (“CARMERA”), a U.S.-based spatial AI company, which specializes in bringing next-generation road intelligence to automated mobility at scale. This is the second major deal for Woven Planet in North America, following the April 2021 announcement to acquire Level 5, the self-driving division of Lyft.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210714005892/en/
Proof of Concept in Tokyo (Still) (Graphic: Business Wire)
Once the deal is closed, the CARMERA team will report into the Automated Mapping Platform (“AMP”) organization of Woven Alpha, Inc. (“Woven Alpha”). Woven Alpha focuses on exploring new strategic areas for business expansion and incubates several innovative projects such as Woven City and Arene, which is Woven Planet’s open software platform. AMP is a connected crowdsourced software platform that supports the creation, development and distribution of high definition (“HD”) maps—a key enabler for smart and safe automated mobility.
The Woven Alpha team plans to develop AMP to become the most globally comprehensive road and lane network HD map platform, enabling high-precision localization support to automated vehicles. The acquisition of CARMERA will accelerate AMP’s shift from the R&D stage to the next phase of commercialization by bolstering the platform’s engineering team with top experts in the development of HD maps. In addition, it will provide access to CARMERA’s sophisticated map update, change management and IoT sensing technology.
Together, the teams will tap into CARMERA’s ability to successfully update HD maps from crowdsourced, camera-based inputs—a significantly cheaper and faster approach than traditional methods. This will strengthen AMP’s ability to serve a comprehensive set of road classes and features, reflecting changes in lane markings, traffic signals, signs and more in near real-time, and support its future multi-regional commercial launch.
CARMERA will join Woven Planet Group as a wholly-owned subsidiary, expanding the company’s footprint beyond its Tokyo headquarters by adding New York and Seattle offices to its planned offices in Silicon Valley and London.
Comment from Mandali Khalesi, Vice President of Automated Driving Strategy and Mapping, Woven Planet:
“AMP has been a key project of Woven Planet since its foundation, helping support its vision of ‘Mobility to Love, Safety to Live.’ We’ve been progressing steadily in bringing safe automated mobility to the passenger and commercial vehicle segments, such as our recent announcements with Isuzu Motors Limited and Hino Motors, Ltd., and with Mitsubishi Fuso Truck and Bus Corporation. I’m really excited to welcome CARMERA to Woven Planet. With CARMERA joining the team, we’ll be able to hit the accelerator. CARMERA’s software stack, which is focused on real-time HD map changes and proprietary hardware custom-tailored to crowdsourcing, is an ideal complement to AMP’s mapping efforts. In addition, their world-class experts will allow us to bring forward the execution of key strategic milestones and jumpstart operations in the United States.”
Comment from Ro Gupta, CEO and Co-founder, CARMERA:
“Woven Planet and AMP have been highly aligned with CARMERA’s culture and mission from the beginning. Our teams have a common view of the unmet need for ubiquity in advanced mobility data going forward, including maps. Woven Planet, thanks to its software-first automotive DNA, shares our commitment to the end-user—to creating a technology stack that can be used safely and without friction by all stakeholders from data originators through to data consumers. This validates and furthers our founding thesis that richer, faster spatial intelligence is both critical to the next generation of ‘Mobility for All’ and viable at global-production scale. I’m beyond excited for CARMERA to join the Woven Planet organization, as it continues to strengthen its footprint in North America and ramp up its software-first development of mobility innovations.”
An earlier partnership between Woven Planet—under its predecessor organization Toyota Research institute - Advanced Development, Inc.—and CARMERA in Tokyo, Detroit and Ann Arbor, Michigan, laid the groundwork for this deal. Woven Planet and CARMERA participated in collaborative projects in 2018, 2019 and 2020, which proved the companies can successfully develop and update HD maps from commodity, device-agnostic sources, such as commercially available dashboard-mounted cameras.
About Woven Planet Group
Woven Planet Group represents a carefully curated blend of expertise and resources dedicated to bringing the vision of “Mobility to Love, Safety to Live” to life. Through innovations and investments in automated driving, robotics, smart cities, and more, we are transforming how humankind lives, works, and moves. We exist to design, build, and deliver secure, connected, and sustainable mobility solutions that benefit all people worldwide. Founded in 2018 as Toyota Research Institute - Advanced Development (TRI-AD), Woven Planet Group is composed of four complementary companies: Woven Planet Holdings, Woven Core, Woven Alpha, and Woven Capital.
For more information, please visit: https://www.woven-planet.global/
About CARMERA
CARMERA is a spatial AI company, built on the revolution of vehicular crowdsourcing and remote sensing to capture street-level change, at global breadth and high definition depth. CARMERA employs an open systems approach to working with the world’s leading automotive companies, commercial mobility operators, and mapping platforms. With a team hailing from leading geospatial, machine learning and computer vision organizations, and venture backing from GV (Google Ventures) among others, the company is headquartered in New York City and Seattle. CARMERA is the recipient of multiple industry awards, including Frost & Sullivan’s 2020 North American Mapping Company of the Year.
For more information, please visit: https://www.carmera.com/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210714005892/en/
Contact information
Woven Planet Holdings, Inc.
pr@woven-planet.global
https://www.woven-planet.global/
CARMERA, Inc.
press@carmera.com
https://www.carmera.com/
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 11:00:00 EET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 11:00:00 EET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 11:00:00 EET | Press release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 10:00:00 EET | Press release
Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity. Pimicotinib, a colony stimulating factor-1 receptor (CSF-1R) inhibitor developed by Abbisko Therapeutics Co., Ltd., Shanghai, China, is the first Chemical Drug Class 1 approved in China for the treatment of TGCT. “We are continuing to deliver on our commitment to improving the lives of patients with rare tumors with this first-in-the-world regulatory approval of pimicotinib,” said Danny Bar-Zohar, CEO Healthcare and Member of the Executive Board of Merck. “This approval is a significant step forward in further strengthening our leadership in rare tumors, while offering patients the opportunity to change the course of
Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 09:44:00 EET | Press release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom